Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC). Axitinib population pharmacokinetic and pharmacokinetic/pharmacodynamic relationships were evaluated. Using nonlinear mi...

Full description

Saved in:
Bibliographic Details
Main Authors: Rini, Brian I., Garrett, May, Poland, Bill, Dutcher, Janice P., Rixe, Olivier, Wilding, George, Stadler, Walter M., Pithavala, Yazdi K., Kim, Sinil, Tarazi, Jamal, Motzer, Robert J.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4175417/
https://ncbi.nlm.nih.gov/pubmed/23553560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.73
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items